Sutro Biopharma, Inc. (STRO)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 2
Do Nothing: fundamentalScore is 2 (strategy requires at least 3 before any bullish entry), and the latest regular-session tape also shows a 5.64% overnight gap above the 5% protectability threshold.
Company overview
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on developing protein-based therapeutics for cancer and autoimmune disorders. Utilizing its proprietary XpressCF+ platform, Sutro is advancing two lead antibody-drug conjugate candidates in Phase 1 trials. The company collaborates with partners like Merck and Celgene to enhance its research and development efforts.
Fundamental
weakSutro Biopharma is a clinical-stage biotech with no approved products and ongoing financial losses.
Clinical-stage biotechnology company with volatile collaboration revenue and ongoing heavy losses/cash burn. Recent SEC filings show roughly $164M of cash and marketable securities and state a cash runway extending into 2028, reducing near-term financing pressure. However, profitability remains far off, free cash flow is deeply negative, and the investment case is primarily driven by clinical and partnership catalysts rather than operating fundamentals.
Sentiment
fairMedia sentiment has deteriorated, and retail interest is minimal, with recent cautious coverage.
An announced Q2 2026 earnings/pipeline update (including early STRO-004 Phase 1 commentary) is the key near-term catalyst, alongside a recent sell-side initiation. Media sentiment has deteriorated versus the prior 30–90 days (polarity_score ~ +0.35 → ~ -0.23) and Reddit discussion is minimal; no regulator-confirmed investigation surfaced (court-case scan was CAPTCHA-limited).
Technical
weakThe stock is in a downtrend, sitting on its 200-day average, with potential for a countertrend bounce.
Short-term structure is weak. Price is below SMA20, SMA50, EMA9, and EMA21 after a high-volatility gap-down; ADX 30.73 confirms trend strength but in a bearish direction. RSI 34.87 and a slightly positive MACD histogram suggest reflex-bounce potential near the 200-day average, but not a clean bullish swing setup.
You’re looking at 2026-08-12 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.